Processa Pharmaceuticals, Inc.
PCSADrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How PCSA's past catalysts played out
PCS12852
Gastroparesis
PCS6422 and capecitabine
Breast Cancer
RX-3117
Metastatic Pancreatic Cancer
PCS499
Necrobiosis Lipoidica
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PCS12852 | Phase 2 | Gastroparesis | - | - |
PCS6422 and capecitabine | Phase 2 | Breast Cancer | - | - |
RX-3117 | Phase 2 | Metastatic Pancreatic Cancer | - | - |
PCS499 | Phase 2 | Necrobiosis Lipoidica | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Processa Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Processa Pharmaceuticals, Inc.'s (PCSA) pipeline across Phase 2. Its lead program is PCS12852 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Processa Pharmaceuticals, Inc.'s next FDA catalyst?→
Processa Pharmaceuticals, Inc.'s (PCSA) next tracked catalyst is a Phase 2 expected September 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PCSA biotech catalysts?→
Add PCSA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Processa Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.